Molecular Biomedicine, Institute of Integrative Biology, ETH Zürich, Wagistrasse 27, 8952 Zürich, Switzerland.
Nat Rev Drug Discov. 2010 Sep;9(9):703-18. doi: 10.1038/nrd2805.
Cytokines are key instigators and regulators of immune responses and therefore hold great potential as targets for new therapeutic strategies. However, the selection of which cytokines to target, and in particular the identification of which cytokines regulate the rate-limiting steps of disease pathways, is crucial to the success of such strategies. Moreover, balancing the need for ablating pathological inflammatory responses and simultaneously maintaining the ability to control infectious agents is a key consideration. Recent advances in our understanding of cytokine networks, as well as technical progress in blocking cytokines in vivo, are likely to be a source for new drugs that can control chronic inflammatory diseases.
细胞因子是免疫反应的关键启动子和调节剂,因此具有作为新治疗策略靶点的巨大潜力。然而,选择要靶向的细胞因子,特别是确定哪些细胞因子调节疾病途径的限速步骤,对于这些策略的成功至关重要。此外,平衡消除病理性炎症反应的需求与同时维持控制感染因子的能力是一个关键考虑因素。我们对细胞因子网络的理解的最新进展,以及在体内阻断细胞因子的技术进展,很可能成为控制慢性炎症性疾病的新药的来源。